Literature DB >> 2498314

Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation.

R L Cohen1, J Niclas, W M Lee, T C Wun, C W Crowley, A D Levinson, J E Sadler, M A Shuman.   

Abstract

Expression of plasminogen activators (PA) has been reported to be associated with invasive tumor growth and increased metastatic ability. In order to delineate changes in PA and PA inhibitor (PAI) expression that accompany cellular transformation, we studied oncogene-containing variants of the Rat-1 cell line. We report here that transfection of the oncogenes v-src, erbB, c-myc, v-myc, N-myc, and EJras into these cells does not result in detectable PA activity in conditioned media or cell extracts. In addition, Northern blot analysis fails to demonstrate urokinase mRNA in Rat-1 cells or transfectants. Moreover, cells transformed by EJras and v-src but not other oncogenes secrete an active placental-type PAI, PAI-2. Using inducible EJras constructs, we find that increased PAI-2 gene expression is detectable within 6-12 h after treatment with the inducing agent. Peak expression of PAI-2 mRNA is increased 10-15-fold over base line, and high levels are maintained for at least 72 h. In contrast to the results with PAI-2, secretion of endothelial-type PAI-1 into conditioned media is sharply down-regulated by several oncogenes. Thus, we have found that PAI-1 and PAI-2 are independently regulated in transformed variants of Rat-1 cells. The specific induction of PAI-2 in cells transformed by oncogenic ras and src suggests that this protease inhibitor may have a previously unsuspected role in malignancy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498314

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1.

Authors:  G C Prendergast; L E Diamond; D Dahl; M D Cole
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

Review 2.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

3.  P52PAI-1 gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: mechanism of induction and involvement in the morphological response.

Authors:  P J Higgins; M P Ryan; D M Jelley
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

4.  Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression.

Authors:  F W Thalacker; M Nilsen-Hamilton
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

5.  p52(PAI-1) and actin expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells.

Authors:  P J Higgins; M P Ryan
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

6.  Repression of stromelysin metalloprotease expression in rat fibrosarcoma cells by dimethylsulfoxide.

Authors:  P Popowicz; G Engel; H Marshall; S Linder
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

7.  Cell-shape-dependent modulation of p52(PAI-1) gene expression involves a secondary response pathway.

Authors:  P J Higgins; L Staiano-Coico; M P Ryan
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

8.  Cell-shape regulation and matrix protein p52 content in phenotypic variants of ras-transformed rat kidney fibroblasts. Functional analysis and biochemical comparison of p52 with proteins implicated in cell-shape determination.

Authors:  P J Higgins; P Chaudhari; M P Ryan
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

Review 9.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Authors:  D Foucré; C Bouchet; K Hacène; N Pourreau-Schneider; A Gentile; P M Martin; A Desplaces; J Oglobine
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.